Solve death with synthetic replacements

We are not a traditional hard-tech company, nor do we follow conventional approaches. Instead, we channel our efforts and resources through a DAO framework (Swiss Association, Vereln). To align incentives and governance, we will launch the $SCBRG governance token, allocating 50% to the community.

Through the DAO, we will fund research and development focused on survival-critical technologies that other investors typically overlook or underfund. Any resulting IP will be delivered to market by a separate incorporation, Sciborg Inc., or by bridge licensing to MedTech & Pharma. At the same time, we will invest in startups working on technologies that lie on the critical path to cyborgization, who can also exit to MedTech & Pharma.

We recognize we can't develop or influence every essential technology — and we don't need to. Many advancements, like robotics and brain–machine interfaces, already have solid backing. Our role is to identify and support underfunded gaps between us and our North Stars, then integrate those emerging solutions with more mature ones to create a cohesive system: the ultimate cyborg package.